Prolia (Amgen) has faced US biosimilar competition since 2025. Denosumab biosimilars launched in the US from mid-2025. Bone health.
Prolia's US exclusivity date is based on generics launched. US biosimilars have already launched, so the loss of exclusivity is under way. It is a biologic, so copies are biosimilars. Biosimilars are harder to make and usually erode sales more gradually than generics.
Prolia is 12% of Amgen's 2025 revenue ($4.4B of $36.8B). With Enbrel, the drugs tracked here add up to 18% of Amgen's revenue losing US exclusivity by 2029.
Bars show each company's tracked drugs as a share of its total 2025 revenue. Prolia is highlighted.